Low-level lead exposure increases systolic arterial pressure and endothelium-derived vasodilator factors in rat aortas

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Fiorim, Jonaina ^a   Ribeiro Jr , Rogério F ^a   Silveira, Edna A ^a   Padilha, Alessandra S ^a   Vescovi, Marcos Vinícius A ^a   de Jesus, Honério C ^a   Stefanon, Ivanita ^a   Salaices, Mercedes ^c   Vassallo, Dalton V ^a,b  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria   (Brazil)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMINOGUANIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LEAD; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; TETRYLAMMONIUM; ENDOTHELIUM DERIVED RELAXING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE RELAXATION; LEAD BLOOD LEVEL; LEAD POISONING; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VASCULAR RING; VASODILATATION; ANIMAL; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; EVALUATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; AORTA; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; LEAD; LEAD POISONING; MALE; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; SODIUM-POTASSIUM-EXCHANGING ATPASE; VASOCONSTRICTION;

EID: 79952137519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017117     Document Type: Article

References (53)

1. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E, (2006) Blood lead below 0,48 μmol/L (10 μg/dL) and mortality among US adults. Circulation 114: 1388-1394.
2. Vaziri ND, Gonick HC, (2008) Cardiovascular effects of lead exposure. Ind J Med Res 128: 426-435.
3. Patrick L, (2006) Lead Toxicity, a review of the literature. Part I: Exposure, Evaluation, and treatment. Altern Med Rev 11 (1): 2-22.
4. Healey N, (2009) Lead Toxicity, vulnerable subpopulations and emergency preparedness. Radiat Prot Dosimetry 134 (3-4): 143-151.
5. Roncal C, Mu W, Reungjui S, Kim KM, Henderson GN, et al. (2007) Lead, at Low Levels, Accelerates Arteriolopathy and Tubulointerstitial Injury in Chronic Kidney Disease. Am J Physiol Renal Physiol 293: 1391-1396.
6. Ehrlich R, Robins T, Jordaan E, Miller S, Mbuli S, et al. (1998) Lead absorption and renal dysfunction in South African battery factory. Occup Environ Med 55: 453-460.
7. Muntner P, He J, Vupputuri S, Coresh J, Batuman V, (1996) Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 63: 104-150.
8. Glenn SB, Bandeen-Roche K, Lee BK, Weaver VM, Todd AC, et al. (2006) Changes in systolic blood pressure associated with lead in blood and bone. Epidemiology 17: 538-544.
9. Glenn SB, Stewart WF, Links JM, Todd AC, Schwartz BS, (2003) The longitudinal association of lead with blood pressure. Epidemiology 14 (1): 30-36.
10. Navas-Acien A, Schwartz BS, Rothenberg SJ, Hu H, Silbergeld EK, et al. (2008) Bone lead levels and blood pressure endpoints: A Meta-Analysis. Epidemiology 19 (3): 496-504.
11. Carmignani M, Boscolo P, Poma A, Volpe AR, (1999) Kininergic system and arterial hypertension following chronic exposure to inorganic lead. Immunopharmacology 44 (1-2): 105-110.
12. Carmignani M, Volpe AR, Boscolo P, Qiao N, Gioacchino M, et al. (2000) Catcholamine and oxide nitric systems as targets of chronic lead M exposure in inducing selective functional impairment. Life Sci 68: 401-451.
13. Grizzo LT, Cordellini S, (2008) Perinatal Lead exposure affects nitric oxide and cyclooxygenase pathways in aorta of weaned rats. Toxicol Sc 103 (1): 207-214.
14. Piccinini F, Favalli L, Chiari MC, (1977) Experimental investigations on the concentration induced by lead in arterial smooth muscle. Toxicology 8 (1): 43-51.
15. Boscolo P, Carmignani M, (1988) Neurohumoral blood pressure regulation in lead exposure. Environ Health Perspect 78: 101-109.
16. Chang HR, Chen SS, Tsao DA, Cheng JT, Ho CK, et al. (1997) Reduced vascular beta-adrenergic receptors and catecholamine response in rats with lead induced hypertension. Arch Toxicol 71: 778-781.
17. Weiler E, Khalil-Manesh F, Gonick H, (1988) Effects of lead and natriuretic hormone on kinetic of sodium potassium ATPase: possible relevance to hypertension. Environ Health Presp pp. 113-115.
18. Watts SW, Chai S, Webb CR, (1995) Lead acetate-induced contraction in rabbit mesenteric artery: interaction with calcium and protein kinase C. Toxicology 99: 55-65.
19. Sharifi AM, Darabi R, Akbarloo N, Larijani B, Khoshbaten A, (2004) Investigation of circulatory and tissue ACE activity during development of lead-induced hypertension. Toxicol Lett 153: 233-238.
20. Vaziri ND, Liang K, Ding Y, (1999) Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 56: 1492-1498.
21. Vaziri ND, Ding Y, Ni Z, (1999) Nitric oxide synthase expression in the course of lead-induced hypertension. Hypertension 34: 558-562.
22. Triggle CR, Hollenberg M, Anderson TJ, Ding H, Jiang Y, et al. (2003) The endothelium in health and disease- A target for therapeutic intervention. J Smooth Muscle Res 39 (6): 249-267.
23. Vanhoutte PM, Shimokawa H, Tang EH, Félétou M, (2009) Endothelial dysfunction and vascular disease. Acta Pysiol (Oxf) 196 (2): 193-222.
24. Karimi G, Khoshbaten A, Abdollahi M, Sharifzadeh M, Namiranian K, (2002) Effectes of subacute lead acetate administration on nitric oxide and cyclooxygenase pathways in rat isolated aortic ring. Pharmacol Res 46 (1): 31-37.
25. Heydari A, Norouzzadeh A, Khoshbaten A, Asgari A, Ghasemi A, et al. (2006) Effects of short-term and subchronic lead poisoning on nitric oxide methabolites and vascular responsiveness in rat. Toxicol Lett 166: 88-94.
26. Zhang LF, Peng SQ, Wang S, (2009) Decreased aortic contractile reaction to 5-hydroxytryptamine in rats with long-term hypertension induced by lead (Pb+2) exposure. Toxicol Lett 186: 78-83.
27. Kosnett MJ, Wedeen RP, Rothenberg SJ, Hipkins KL, Materna BL, et al. (2007) Recommendations for medical management of adult lead exposure. Environ Health Perspect 115 (3): 463-71.
28. Agency for Toxic Substances and Disease Registry (ATSDR) (2005) Toxicological profile for lead Atlanta U.S. Department of Health and Human Services, Public Health Service.
29. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND, (1997) Lead Induce Hypertension. Interplay of nitric oxide and reactive oxygen species. Hypertension 30 (6): 1487-1492.
30. Marques M, Millás I, Jiménes A, Gárcia-Colis E, Rodrigues-Feo JA, et al. (2001) Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol 12: 2594-2600.
31. Koresková-Sysalová J, (1997) Determination of cadmium and lead levels in human blood of a general Czech population by GAAS. Biological Trace Element Research 56: 321-329.
32. + ATPase activity in vascular smooth muscle. Blood Vessels 15: 198-207.
33. +-ATPase in ouabain- induced hypertension. Br J Pharmacol 135 (3): 771-81.
34. Oliveira EM, Santos RA, Krieger JE, (2000) Standartization of a fluorimetric assay for the determination of tissue angiotensin-converting-activity in rats. Braz J Med Res 33 (7): 755-64.
35. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA, (1994) Nitric Oxide directly activates calcium-dependent potassium channel in vascular smooth muscle. Nature 368 (6474): 850-853.
36. Centers for Disease Control and Prevention (CDC) (2005) Blood lead levels- United States, 1999-2002. MMWR Morb Mortal Wkly Rep 54: 513-516.
37. Bener A, Obineche E, Gillett M, Pasha MA, Bishawi B, (2001) Association between blood levels of lead, blood pressure, and risk of diabetes and heart disease in workers. Int Arch Occup Environ Health 74: 375-378.
38. Harlan WR, (1988) The relationship of blood lead levels to blood pressure in the U.S. population. Environ Health Perspect 78: 9-13.
39. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ, (2007) Lead exposure in cardiovascular disease -A systematic review. Environ Health Perspect 115: 472-482.
40. Goodfriend TL, Ball DL, Elliott ME, (1995) Lead increase aldosterone production by rat adrenal cells. Hypertension 25: 785-789.
41. Campbell BC, Meredith PA, Scott JJ, (1985) Lead exposure and changes in the renin-angiotensin-aldosterone system in man. Toxicol Lett 25: 25-32.
42. Courtois E, Marques M, Barrientos A, Casado S, Lópes-Farré A, (2003) Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygensase-2. J Am Soc Nephrol 14: 1464-1470.
43. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, et al. (1999) Activation of nitric oxide syntase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
44. McCabe TJ, Fulton D, Roman LJ, Sessa WC, (2000) Enhanced electron flux and reduced calmodulin dissociation may explain "Calcium dependent" eNOS activation by phosphorilation. J Biol Chem 275 (9): 6123-6128.
45. Silveira EA, Lizardo JHF, Souza LP, Stefanon I, Vassallo DV, (2010) Acute lead-induced vasoconstriction in vascular beds of isolated perfused rat tails in endothelium-dependent. Braz J Med Biol Res 43 (5): 492-499.
46. Vaziri ND, Ding Y, (2001) Effects of lead on nitric oxide synthase expression on coronary endothelial cells: a role of superoxide. Hypertension 37 (2): 223-6.
47. Vaziri ND, Ding Y, Ni Z, Gonick H, (1997) Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension. Kidney Int 52: 1042-1046.
48. Vaziri ND, Ding Y, Ni Z, (2001) Compensatory Up-regulation of nitric oxide syntase isoforms in lead-induced hypertension; Reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 298: 679-685.
49. Félétou M, (2009) Calcium-activated potassium channels and endothelial dysfunction: Therapeutic options? Br J Pharmacol 156: 545-562.
50. Pueyo ME, Arnal JF, Rami J, Michel JB, (1998) Angiotensin II stimulates the production of NO and peroxinitrite in endothelial cells. Am J Physiol 247: 214-220.
51. + pump activity in cultures of smooth muscle from rat aorta. Proc Natl Acad Sc USA 79 (5): 1438-1442.
52. +-ATPase activity by nitric oxide: a cGMP-independent effect. Am J Physiol 266 (35): H2146-H251.
53. + pump involves the phosphatidylinositol-3 kinase and p42/44 mitogen-actived protein kinase signaling pathways in vascular smooth muscle cells. Endocrinology 145: 1151-1160.